Hormone replacement therapy (HRT) for transgender and transsexual people replaces the hormones naturally occurring in their bodies with those of the other sex. However, not all cases of hormone replacement therapy are used by transgendered people. Some reasons for this include men who wish to have a hair-free body, as a result of less of the testosterone, androgens in their body. Its purpose is to cause the development of the secondary sex characteristics of the desired gender. It can not undo the changes produced by the first natural occurring puberty of transgender people, this is done by sexual reassignment surgery and for transwomen by epilation. Some intersex people also receive HRT, either starting in childhood to confirm the gender they were assigned, or later, if this assignment has proven to be incorrect.
While some argue that hormonal therapy does not truly masculinize or feminize, the question is one of definitions. If by masculinize and feminize one means to completely reproduce the male or female biological state, that cannot be done with current medical or surgical therapy. However, the goal of HRT, and indeed all somatic treatments, is to provide patients with a more satisfying body that is more congruent with their true psychological gender identity. It should be noted that the effects of hormonal therapy are often much more satisfying to transgender men than transgender women. It is easier to produce secondary male sexual characteristics with androgens than it is to rid transgender women of those established characteristics.
- 1 Formal requirements for HRT
- 2 Changes established at puberty
- 3 Changes
- 4 Contraindications
- 5 Types of therapy
- 6 Hormone effects
- 7 References
- 8 See also
- 9 External links
Formal requirements for HRT
The requirements for hormone replacement therapy vary immensely, often at least a certain time of psychological counselling is required, and so is a time of living in the desired gender role, if that is at all possible, in order to assure that they can psychologically function in that gender role. This period is sometimes called the Real Life Experience (RLE). See also Standards of care for gender identity disorders.
Some individuals choose to self-administer their medication ("do-it-yourself"), often because available doctors have too little experience in this matter, or no doctor is available in the first place. Sometimes, trans persons choose to self-administer because their doctor will not prescribe hormones without a letter from the patient's therapist stating that the patient meets the diagnostic criteria for GID and is making an informed decision to transition. Many therapists require at least 3 months of continuous psychotherapy and/or a real life test in order to write such a letter as is suggested in the HBIGDA Standards of Care. In these circumstances, the individual may self-administer until they can get these authorizations, feeling that they shouldn't have to wait for a medical professional to be convinced of their situation. In addition, as many individuals must pay for evaluation and care out-of-pocket, expense can also be prohibitive to pursuing such therapy.
However, self-administration of hormones is potentially dangerous. Individuals seeking physicians who are knowledgeable and willing to treat transgender patients may wish to consult transgender support groups or a directory of LGBT-friendly doctors, in the USA for example the Gay and Lesbian Medical Association's referral service at GLMA.org.
Changes established at puberty
A number of skeletal and cartilaginous changes take place after the onset of puberty at various rates and times. Sometime in the late teen years epiphyseal clusure (in other words, the ends of bones are fused closed) takes place and the length of bones is fixed for life. Consequently total height and the length of arms, legs, hands, and feet are not affected by HRT. However, details of bone shape change throughout life, bones becoming heavier and more deeply sculptured under the influence of testosterone. Many of these differences are described in the Desmond Morris book Manwatching.
- Pelvis: The pelvis in females tends to be wider than in males and tilted forward; the pelvis in males tends to be more circular and tilted upwards.
- Hands: Male hands and feet tend to be larger than female hands and feet in persons of equal height.
- Upper Arm: The upper arm in females tends to be significantly longer (about 1") than in males of the same height.
- Head: Females tend to have smaller heads than males of the same height.
- Chest: Female ribcages tend to be narrower than those of males in the same height.
Facial changes develop gradually over time, and sexual dimorphism (physical difference between the sexes) tends to increase with age. Within a population of similar body size and ethnicity:
- Brow: Males tend to develop heavier bony brows than females.
- Cheeks: Female cheeks tend to be fuller and more rounded. Under the influence of estrogen, fat is deposited beneath the skin and overall facial and body contours become softer.
- Nose: The tips of the nasal bones tend to grow more in males than females, creating a larger (longer or wider) nose.
- Jaw: The jaw in males tends to grow wider and more deeply sculptured than in females.
- Larynx: At puberty, the bones and cartilage of the voicebox tend to enlarge less in females than males. In some males, the larynx becomes visible as a bony "adam's apple."
- Lips: Females tend to have thicker, fleshier lips than males of the same size.
- the growth of breasts, with concomitant enlargement of the nipples, and
- redistribution of body fat.
- thinning of skin.
- breast development,
- enlarged nipples and areolae
- stretch marks (for some)
- decreased libido,
- redistribution of body fat,
- reduced muscle development,
- various skin changes,
- significantly reduced body hair
- change in body odor and sweat production,
- less prominence of veins,
- ocular changes,
- gonadal size
The psychological changes are harder to define, because HRT is usually the first physical action that takes place when transitioning. This fact alone has a significant psychological impact, which is hard to distinguish from hormonally induced changes. Many also report feeling more confident.
- Absolute: history of estrogen sensitive cancer (for example breast cancer), history of thromboembolic disease (unless provided with concurrent anti-coagulation therapy), or history of macroprolactinoma.
- Relative: Liver, kidney, or heart disease and stroke (or any of the risk factors for heart disease: high cholesterol, diabetes, obesity, smoking); Strong family history of breast cancer or thromboembolic disease; Gallbladder disease; circulation or clotting conditions such as peripheral vascular disease, polycythemia vera, sickle cell anaemia, paroxysmal nocturnal hemoglobinuria, hyperlipidemia/hypercholesterolemia, hyperlipoproteinaemia, hypertension, factor V leiden, prothrombin mutation, antiphospholipid antibodies, anticardiolipin antibodies, lupus anticoagulants, plasminogen or fibrinolysis disorders, protein C deficiency, protein S deficiency, or antithrombin III deficiency.
Types of therapy
- Doses are often higher than replacement doses for cisgender women. Usually the dosage is reduced after an orchiectomy (the removal of the testes) or sex reassignment surgery. However, the practice of lowering estrogen doses after such operations has been carried over from the days when very high doses of estrogen were required to decrease testosterone since anti-androgens were not used. In fact, high doses (though using a less potent estrogen, estradiol, that is endogenous to the human body rather than the risky ethinyl estradiol and conjugated estrogens used in the past) are recommended during the first ten or so years of HRT to fully develop, with or without having had an orchiectomy or sex reassignment. After usually ten years or so the dosages can be reduced.
- Many different variations of estradiol exist as well as other types of estrogens although the ones most commonly used are either micronized estradiol, estradiol acetate, estradiol valerate, estradiol cypionate, estradiol enanthate, conjugated estrogens, esterified estrogens, and ethinyl estradiol.
- Injectable, implanted, nasal, oral, sublingual, gel, and transdermal patch formulations are available.
- As dosage increases, risks increase as well. Therefore, women with relative contraindications should start at lower doses and increase dosage more gradually.
- Progestogens include progesterone and progestins (synthetic analogs of progesterone or 17-alpha hydroxyprogesterone). There are oral, sublingual, suppository, gel, and injectable formulations available.
- Progestogens are involved in the full maturation of the breasts, particularly the mammary structures lobules, acini, and alveoli.
- Progestogens also help fat distribution, increase female libidinal feelings, increase appetite, slight increase in skin oil, increases blood flow to the skin, increases the ability to sweat and lose extra heat, increase in body temperature enabling one to better tolerate the cold, healthier nails, produce a sense of calm and promote sleep, and increase energy. Progesterone in particular is essential for bone health and seems to have a role in skin elasticity, and nerve tissue. Other effects that have been seen with progesterone in particular (not the synthetics) include reducing spasms and relaxing smooth muscle tone, gallbladder activity is reduced, bronchi are widened (helps respiration), an anti-inflammatory agent and reduces the immune response, normalizing blood clotting and vascular tone, zinc and copper levels, cell oxygen levels, and use of fat stores for energy. Progesterone also assists in thyroid function and bone building by osteoblasts. However, progestogens may increase skin oil and libido too much for some and there may be acne breakouts due to the increase in skin oil.
- Spironolactone is the most frequently used anti-androgen in the United States because it is relatively safe and inexpensive. Cyproterone acetate is more commonly used outside of the US.
- Spironolactone is a 'potassium sparing diuretic' that is also used to treat low-renin hypertension, edema, hyperaldosteronism, and low potassium levels caused by other diuretics. It can cause high potassium levels, hyperkalemia, and is therefore contra-indicated in people with renal failure or who otherwise have elevated potassium levels. Spironolactone prevents the formation of testosterone in the testis (though not in the adrenals) by inhibiting enzymes involved in its production and is an androgen receptor antagonist (prevents androgens from binding to androgen receptors).
- Cyproterone acetate is derived from 17-alpha hydroxyprogesterone and suppresses luteinizing hormone (which in turn reduces testosterone levels), blocks androgens from binding to androgen receptors, and is a weak progestin. It has been used to treat prostate cancer. If used long-term in dosages of 150 milligrams or higher it can possibly lead to liver damage or failure.
- Other anti-androgens include bicalutamide, flutamide, and nilutamide. Unlike the two medications above, these do not lower testosterone levels but rather prevent testosterone and dihydrotestosterone from binding to androgen receptors. Because these have a weak action at the brain they do not lower libido or decrease erections. Two other anti-androgens that are rarely prescribed are ketoconazole and cimetidine. Ketoconazole has been used in those with prostatic cancer and hirsutism. Cimetidine has also been used in hirsutism. Ketoconazole has the potential of liver toxicity over long-term use and cimetidine is a relatively weak anti-androgen.
- Certain anti-androgens do not lower testosterone levels or prevent its action upon tissues but rather its metabolite, dihydrotestosterone (DHT), from forming. These medications can be used when the patient has male-pattern hair loss (androgenetic alopecia) and/or an enlarged prostate (benign prostatic hyperplasia). DHT contributes to the manifestation and exacerbation of both. Two medications are currently available to prevent the creation of DHT, finasteride and dutasteride. DHT levels can be lowered up to approximately 60-75% with the former depending upon dosage and up to 93-94% with the latter.
- In both sexes, the hypothalamus releases GnRH (gonadotropin-releasing hormone) to stimulate the pituitary to produce LH (luteinizing hormone) and FSH (follicle-stimulating hormone) which in turn cause the gonads to produce sex steroids. In adolescents of either sex with relevant indicators, GnRH agonists, such as goserelin acetate can be used to suspend the advance of sex steroid-induced, inappropriate pubertal changes for a period without inducing any changes in the gender-appropriate direction. GnRH agonists work by initially over stimulating the pituitary then rapidly desensitizing it to the effects of GnRH. After an initial surge, over a period of weeks, gonadal androgen production is greatly reduced. There is considerable controversy over the earliest age, and for how long it is clinically, morally and legally safe to do this. The current, sixth edition of the Harry Benjamin International Gender Dysphoria Association Standards of Care permit from Tanner stage 2, but do not allow the addition of gender-appropriate hormones until 16, which could be five or more years. The sex steroids do have important other functions. Also skeletal growth, which is often considered to be masculinising, is not hindered by GnRH agonists.
- GnRH agonists are often prescribed to prevent the reactivation of testicular function where surgeons require the cessation of estrogens prior to surgery.
- The high cost of GnRH agonists is often a significant factor.
- The most significant cardiovascular risk for transgender women is the pro-thrombotic effect of estrogens (Increased blood clotting.) This manifests most significantly as an increased risk for thromboembolic disease: deep venous thrombosis (DVT) and pulmonary embolism (PE) which occurs when DVTs break off and migrate through the venous system to the lungs. It is important for any person on female hormones to immediately seek medical care if she develops pain or swelling of one leg (especially calf) as this is the predominant symptom of a DVT, or if she develops symptoms of PE: chest pain, shortness of breath, fainting, or palpitations (even without leg pain or swelling).
- In practice this becomes very important to transgender women undergoing surgery. Ethinyl and conjugated oral estrogens should be withheld for a week before and until two weeks after surgery.
- DVTs occur more frequently in the first year of treatment with estrogens. However this may represent a 'screening by treatment' of patients who may have genetic predispositions to thromboembolic disease, with those who are more likely to develop DVTs doing so early on in therapy. However, if patients have a family history of thromboembolic disease, screening for known disease may be appropriate.
- DVT risk is higher with oral estrogen (particularly ethinyl estradiol and conjugated estrogens) rather than injectable, transdermal, implantable, and nasal estrogens.
- DVT risk also increases with age and with smoking, so many clinicians advise using the safer estrogen formulations in patients who smoke or are older than age 40.
- If screening is undertaken for known pro-thrombotic mutations such as Factor V-Leiden, antithrombin III, and protein C or S deficiency, it should be done so to increase the safety of hormonal therapy and not as a screen for who may undertake hormonal therapy. Given that the risk of warfarin treatment in a relatively young, well-informed, and otherwise healthy population is quite low and that the risk of adverse physical and psychological outcome for untreated transgender patients is high, a prothrombotic mutation is not an absolute contraindication for hormonal therapy. (See: Levy, et al. “Endocrine Intervention for Transsexuals” Clin Endo 2003. 59:409-418.)
- The antiandrogen bicalutamide is associated with an increased risk of heart failure when used as monotherapy (without any other drugs). A study of prostate cancer patients also showed an increased number of deaths unrelated to cancer among patients taking 150 mg/day bicalutamide. This prompted Health Canada to withdraw its approval for 150 mg bicalutamide as monotherapy. The increased death rate has not been observed where bicalutamide was combined with a method of reducing androgen production. The exact reasons for the heart failure and deaths have not been completely determined, however a likely cause is acute adrenal insufficiency and hypotension due to the action of DHT during episodes of bicalutamide withdrawal. Because bicalutamide is extremely lipophilic, it is difficult to avoid periods of low serum concentration due to the uptake of bicalutamide into fat cells.
- Current facial hair is only slightly affected (some reduction in density, coverage, and slower growth) by anti-androgens. Those who are less than a decade past puberty and/or whose ethnicity generally lacks a significant amount of facial hair will have better results with anti-androgens. Those taking anti-androgens will have better results with electrolysis/laser hair removal than those who are not. If one is still in their teens or early twenties, there will be prevention of new facial hairs from developing if testosterone levels are within the female range.
- Body hair (chest, periareolar, shoulders, back, abdomen, rear, thighs, tops of hands, tops of feet) will, over time, turn from terminal ("normal") hairs to vellus hairs (very tiny, blonde "baby" hairs). Hair on the arms, perianal, and perineal will reduce but may not turn to vellus hair on the latter two regions (some natal females also have some hair in these areas). Underarm hair will slightly change in texture and length, pubic hair becomes more typically female in pattern. Lower leg hair becomes less dense in concentration. All depend upon genetics.
- Head hair may slightly change in texture, curl, and color (new hairs that is, not hair that has already formed and reached the surface prior to HRT), this is especially likely with hair growth from previously bald areas.
- Eyebrow hair becomes less "bushy" or scattered.
- Transgender women report a sometimes significant reduction in libido all depending upon the dosage of anti-androgens. A small number of post-operative transsexual women may take small amounts of testosterone to boost the libido. Many pre-operative transsexual women simply wait until after sex-reassignment surgery to begin an active sex life (due to how they feel towards their genitals and/or, for heterosexual or bisexual transsexual women, an aversion to anal sex) and for newly post-operative women how satisfied they are with the results. Raising estrogen dosage or adding a progestogen has also raised the libido of some transwomen.
- Spontaneous and morning erections decrease in frequency significantly, however some who have had an orchiectomy still experience morning erections. Voluntary erections can be maintained since the brain is the most important sex organ, a developed repertoire of fantasies and good visualization is a must. It also depends on how one views their own genitals (disgust, strong aversion to, tolerable, etc.).
- Testi volume is reduced by about 25% with typical dosages and as much as 50% in higher dosages, especially after a year of HRT. This is in response to the decrease in Leydig cells, Sertoli cells, and interstitial tissue, which produce both sperm and testosterone. When testosterone is dramatically reduced spermatogenesis is halted almost completely, when the cells that are involved in these processes go unused they atrophy (shrink).
- The prostate shrinks
- The bladder shrinks
- The line that runs down the underside of the penis and down the middle of the scrotum, the peno-scrotal raphe (where the urogenital folds fused early in the womb), will darken.
- Minor water retention is likely
- See also: Male pregnancy
- Childbearing, as experienced by cisgender women, is impossible with today's technology. Pre-operative sperm banking can be done, however, allowing artificial insemination to be used to produce genetic offspring with someone else at a later date. Medical advances in the near future may one day make this possible by using a donor uterus long enough to carry a child to term as anti-rejection drugs do not seem to affect the fetus. The DNA in a donated ovum can be removed and replaced with the DNA of the receiver. Further in the future stem cell biotechnology may also make this possible, with no need for anti-rejection drugs.
- Both estrogens and androgens are necessary in both biological males and females for healthy bone. (Young healthy women produce about 10 mg of testosterone monthly. Higher bone mineral density in males is associated with higher serum estrogen.)
- Bone is not static. It is constantly being reabsorbed and created. Osteoporosis results when bone formation occurs at a rate less than bone reabsorption.
- Estrogen is the predominant sex hormone that slows bone loss (even in men.)
- Both estrogen and testosterone help stimulate bone formation (T, especially at puberty.)
- The hips will rotate slightly forward due to changes in the tendons so hip discomfort is not uncommon.
- Any drug can cause adverse reactions with other medications so it is wise to check with a doctor or pharmacist when starting any new medication.
- Of the estrogen formulations commonly used, ethinyl estradiol (commonly found in birth control pills) has the greatest number of adverse reactions.
- The uppermost layer of skin, the stratum corneum, becomes thinner and therefore more translucent and pinkish (spider veins may appear or be more noticeable), less collagen, more susceptible to tearing and irritation from scratching or shaving, increased tactile sensation, and slightly lighter in color due to a slight decrease in melanin (pigment).
- Skin becomes softer
- Sebaceous gland activity (which is triggered by androgens) lessens which lowers the amount of sebum (oil) production on the skin and scalp, consequently the skin becomes less prone to the formation of acne due to the less quantity of oil that is produced. Dry skin becomes a problem and lotions and oils may be necessary.
- The skin's pores become smaller due to the low quantities of sebum produced
- Body odor (skin, sweat, and urine) will become less "metallic," "sharp," or "acrid" and more "sweet" and "musky."
- Many apocrine glands (type of sweat glands) become inactive and body odor decreases. Sebum also contributes to body odor, the production of which is reduced by anti-androgens (as described above).
- More subcutaneous (under skin) adipose (fat) tissue accumulates. This gives a more puffy/softer appearance. Consequently dimpling, or cellulite, will be more apparent on the thighs and buttocks due to this along with the thinness of the skin.
- Susceptibility to sunburn increases possibly due to the thinner skin and/or less skin pigment.
- Because of the increase in adipose tissue in the hips, thighs, and rear, stretch marks (striae distensae) may appear on the skin in these areas.
- The lens of the eyes changes in curvature
- Due to decreased androgens, the meibomian glands (aka., tarsal, palpebral, or tarsoconjunctival glands. A type of sebaceous gland on the upper and lower eyelids that open at the edges of the lids) produce less oil (oil that makes up the lipid layer of tear film which prevents the evaporation of the watery layer beneath) and a tendency for dry eyes may be a problem.
- Sensitivity to male body odor(s) (including male pheromones) may be positively correlated with elevated estrogen levels. Overall, olefactory senses may increase. Progestogens, however, often lowers the sensitivity to male pheromones.
Mammary gland development
- Breast, nipple, and areolar development takes 4–6 years to complete depending upon genetics, and sometimes as long as 10 years. It is normal for there to be a "stall" in breast growth during feminization, or for the size of one breast to be a little bigger than the other. MtF who undergo HRT often experience breast development which is below the comparable natal female norm (many seek breast augmentation); it is rare for a HRT patient to opt for breast reduction. The size of the rib cage and shoulder width also play a role in the perceivable "size" of the breasts; both characteristics are usually smaller than in natal females, i.e., if a natal female and a transsexual female were to have the same cup size, the transsexual female's breasts would most likely appear smaller. Thus when a transwoman opts to have breast augmentation, the implants used are, on the average, larger than those commonly used by natal females.
- The nipples will become more sensitive to stimulation.
Adipose tissue distribution
- Fat distribution in the body slowly changes over months and years. The body will now tend to accumulate new adipose tissue (fat) in a typically female pattern. This includes the hips, thighs, rear, pubis, upper arms, and breasts. The body will now tend to use/burn the old adipose tissue in the waist making the waist appear smaller as well as on the shoulders and back.
- Subcutaneous adipose tissue increases in the face (cheeks and lips) making the face appear puffier, appears to "round out" the face, and the face appears less "drawn" or "hollow" with slightly less emphasis on the jaw due to the lower portion of the cheeks having filled in.
- Estrogens may predispose to gallbladder disease - especially in older and obese people
- Estrogens (especially oral forms) may cause elevations in transaminases (liver function tests) indicating liver toxicity. LFTs should therefore be periodically monitored in transgender women
- Mood changes can occur - including the development of depression, particularly in those who take progestins
- Migraines can be made worse or unmasked by estrogen therapy
- Estrogens can induce the development of prolactinomas, which is why prolactin levels should periodically be monitored in transgender women. Milk discharge from the nipples can be a sign of elevated prolactin levels. If a prolactinoma becomes large enough, it can cause visual changes (especially decreased peripheral vision), headaches, mood changes, depression, dizziness, nausea, vomiting, and symptoms of pituitary failure like hypothyroidism.
- Recent studies have indicated that cross-hormone therapy in transwomen may result in a reduction in brain volume towards female proportions. It should be noted that brain volume has nothing to do with IQ.
- Estrogen therapy causes decreased insulin sensitivity which places transgender women at increased risk of developing type II diabetes.
- One's metabolism slows down and one tends to gain weight, lose energy, need more sleep, and become cold more easily. Due to androgen deprivation a loss of muscle tone, a slower metabolism, and physical weakness becomes more evident. Building muscle will take twice as much work as before. However, the addition of a progestogen may increase energy although an increase in appetite may be seen as well.
- Orentreich N, Durr NP (July 1974). "Mammogenesis in transsexuals". Journal of Investigative Dermatology 63 (1): 142–146.
- Mauvais-Jarvis P, Kuttenn F et al. (January 1986). "Estradiol-progesterone interaction in normal and pathological human breast cells". Annals of Endocrinology 47 (3): 179–187.
- (1988) in Cooke BA, King RJB, van der Molen HJ (eds.): New Comprehensive Biochemistry: Hormones and Their Actions, Part I vol. 18a. Amsterdam: Elsevier.
- Cyrlak D, Wong CH (December 1993). "Mammographic changes in postmenopausal women undergoing hormonal replacement therapy". American Journal of Roentgenology 161 (6): 1177–1183.
- Gorins A, Denis C (1995). "Effects of progesterone and progestational hormones on the mammary gland". Archives d'anatomie et de cytologie pathologiques 43 (1-2): 28–35.
- Futterweit W (April 1998). "Endocrine therapy of transsexualism and potential complications of long-term treatment". Archives of Sexual Behavior 27 (2): 209–226.
- (1998) "17. Hormonal Therapy in Gender Dysphoria: The Male-to-Female Transsexual", in Denny D (ed.): Current Concepts in Transgender Identity, chap. by Basson R, Prior JC, New York: Garland Publishing.
- Colin, Claude. Hormone Dependence of the Mammary Tissue. Retrieved on June 14, 2008.
- Shyamala G (January 1999). "Progesterone signaling and mammary gland morphogenesis". Journal of Mammary Gland Biology and Neoplasia 4 (1): 89–104.
- Kanhai RC, Hage JJ et al. (January 2000). "Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men". The American Journal of Surgical Pathology 24 (1): 74–80.
- Schams D, Kohlenberg S et al. (May 2003). "Expression and localisation of oestrogen and progesterone receptors in the bovine mammary gland during development, function and involution". Journal of Endocrinology 177 (2): 305–317.
- Lamote I, Meyer E et al. (March 2004). "Sex steroids and growth factors in the regulation of mammary gland proliferation, differentiation, and involution". Steroids 69 (3): 145–159.
- Swerdloff RS, Ng J, and Palomeno GE (March 2004). Gynecomastia: Etiology, Diagnosis, and Treatment. Retrieved on June 14, 2008.
- Baltzell K, Eder S, Wrensch M (January 2005). "Breast carcinogenesis: can the examination of ductal fluid enhance our understanding?". Oncology Nursing Forum 32 (1): 33–39.
- Brisken C. Genetic dissection of signaling pathways important in breast development and breast cancer. Retrieved on June 14, 2008.
- Friess E, Tagaya H et al. (May 1997). "Progesterone-induced changes in sleep in male subjects". American Journal of Physiology 272 (5): E885-E891.
- Montplaisir J, Lorrain J et al. (January–February 2001). "Sleep in menopause: differential effects of two forms of hormone replacement therapy". Menopause 8 (1): 10–16.
- Söderpalm AH, Lindsey S et al. (April 2004). "Administration of progesterone produces mild sedative-like effects in men and women". Psychoneuroendocrinology 29 (3): 339–354.
- van Broekhoven F, Bäckström T, Verkes RJ (November 2006). "Oral progesterone decreases saccadic eye velocity and increases sedation in women". Psychoneuroendocrinology 31 (10): 1190–1199.
- Golparvar M, Ahmadi F, Saghaei M (January 2005). "Effects of progesterone on the ventilatory performance in adult trauma patients during partial support mechanical ventilation". Archives of Iranian Medicine 8 (1): 27–31.
- Menard RH, Stripp B, Gillette JR (June 1974). "Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism". Endocrinology 94 (6): 1628–1636.
- Stripp B, Taylor AA et al. (October 1975). "Effect of spironolactone on sex hormones in man". The Journal of Clinical Endocrinology and Metabolism 41 (4): 777–781.
- Pozzi AG, Ceballos NR (August 2000). "Human chorionic gonadotropin-induced spermiation in Bufo arenarum is not mediated by steroid biosynthesis". General and Comparative Endocrinology 119 (2): 164–171.
- Canosa LF, Ceballos NR (August 2001). "Effects of different steroid-biosynthesis inhibitors on the testicular steroidogenesis of the toad Bufo arenarum". Journal of Comparative Physiology 171 (6): 519–526.
- Boisselle A, Dionne FT, Tremblay RR (July 1979). "Interaction of spironolactone with rat skin androgen receptor". Canadian Journal of Biochemistry 57 (7): 1042–1046.
- Yamasaki K, Sawaki M et al. (February 2004). "Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals". Toxicology 195 (2-3): 177–186.
- Kaiser E, Gruner HS (1987). "Liver structure and function during long-term treatment with cyproterone acetate". Archives of Gynecology 240 (4): 217–223.
- Willemse PH, Dikkeschei LD et al. (March 1988). "Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer". European Journal of Cancer & Clinical Oncology 24 (3): 417–421.
- Hinkel A, Berges RR et al. (1996). "Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow-up of 89 patients". European Urology 30 (4): 464–470.
- Watanabe S, Cui Y et al. (September 1997). "Follow-up study of children with precocious puberty treated with cyproterone acetate". Journal of Epidemiology 7 (3): 173–178.
- Migliari R, Muscas G et al. (December 1999). "Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy". The Italian Archives of Urology, Andrology 71 (5): 293–302.
- Laron Z, Kauli R (July 2000). "Experience with cyproterone acetate in the treatment of precocious puberty". Journal of Pediatric Endocrinology & Metabolism 13 (Suppl 1): 805–810.
- Giordano N, Nardi P et al. (September 2001). "Acute hepatitis induced by cyproterone acetate". The Annals of Pharmacotherapy 35 (9): 1053–1055.
- Lin AD, Chen KK et al. (December 2003). "Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer". Journal of the Chinese Medical Association 66 (12): 735–740.
- Savidou I, Deutsch M et al. (December 2006). "Hepatotoxicity induced by cyproterone acetate: a report of three cases". World Journal of Gastroenterology 12 (46): 7551–7555.
- Henriksson P, Eriksson A et al. (1988). "Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate". Prostate 13 (3): 257–261.
- von Schoultz B, Carlström K et al. (1989). "Estrogen therapy and liver function--metabolic effects of oral and parenteral administration". Prostate 14 (4): 389–395.
- Aro J, Haapiainen R et al. (1990). "The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients". European Urology 17 (2): 161–165.
- Henriksson P, Blombäck M et al. (March 1990). "Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma". British Journal of Urology 65 (3): 282–285.
- Aro J (1991). "Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population". Prostate 18 (2): 131–137.
- Henriksson P, Stege R (1991). "Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer". International Journal of Technology Assessment in Health Care 7 (2): 220–225.
- Henriksson P (January–February 1991). "Estrogen in patients with prostatic cancer. An assessment of the risks and benefits.". Drug Safety 6 (1): 47–53.
- Caine YG, Bauer KA et al. (October 1992). "Coagulation activation following estrogen administration to postmenopausal women". Thrombosis and Haemostasis 68 (4): 392–395.
- Stege R, Sander S (March 1993). "Endocrine treatment of prostatic cancer. A renaissance for parenteral estrogen". Tidsskrift for den Norske laegeforening 113 (7): 833–835.
- Stege R, Carlström K et al. (September 1995). "Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status". Der Urologe. Ausg. A 34 (5): 398–403.
- Cox RL, Crawford ED (December 1995). "Estrogens in the treatment of prostate cancer". Journal of Urology 154 (6): 1991–1998.
- Henriksson P, Carlström K et al. (July 1999). "Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen.". Prostate 40 (2): 76–82.
- Hedlund PO, Henriksson P (March 2000). "Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality". Urology 55 (3): 328–333.
- Hedlund PO, Ala-Opas M et al. (2002). "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer – Scandinavian Prostatic Cancer Group (SPCG) Study No. 5". Scandinavian Journal of Urology and Nephrology 36 (6): 405–413.
- Ockrim J, Lalani el-N, Abel P (2006). "Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy". Nature Clinical Practice. Oncology 3 (10): 552–563.
- Basurto L, Saucedo R et al. (2006). "Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women". Gynecologic and Obstetric Investigation 61 (2): 61–64.
- Hemelaar M, Rosing J et al. (July 2006). "Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women". Arteriosclerosis, Thrombosis, and Vascular Biology 26 (7): 1660–1666.
- Hedlund PO, Damber JE et al. (2008). "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.". Scandinavian Journal of Urology and Nephrology 42 (3): 220–229.
- Canonico M, Plu-Bureau G, et al. (May 2008). "Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis". British Medical Journal 336 (7655): 1227–1231.
- Casodex monograph. Retrieved on June 14, 2008.
- Iversen P, Johansson JE et al. (November 2004). "Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6". Journal of Urology 172 (5): 1871–1876.
- Important Safety Information Regarding Casodex 150 mg. Retrieved on June 14, 2008.
- Asscheman H, Gooren LJ (1992). Hormone Treatment in Transsexuals. Retrieved on June 13, 2008. Cite error: Invalid
<ref>tag; name "Gooren1992" defined multiple times with different content Cite error: Invalid
<ref>tag; name "Gooren1992" defined multiple times with different content Cite error: Invalid
<ref>tag; name "Gooren1992" defined multiple times with different content Cite error: Invalid
<ref>tag; name "Gooren1992" defined multiple times with different content Cite error: Invalid
<ref>tag; name "Gooren1992" defined multiple times with different content
- Giltay EJ, Gooren LJ (August 2000). "Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females". Journal of Clinical Endocrinology and Metabolism 85 (8): 2913–2921.
- Doctors plan uterus transplants to help women with removed, damaged wombs have babies - Associated Press
- Fageeh W, Raffa H et al. (March 2002). "Transplantation of the human uterus". International Journal of Gynaecology and Obstetrics 76 (3): 245–251.
- Del Priore G, Stega J et al. (January 2007). "Human uterus retrieval from a multi-organ donor". Obstetrics and Gynecology 109 (1): 101–104.
- Nair A, Stega J et al. (April 2008). "Uterus Transplant: Evidence and Ethics". Annals of the New York Academy of Sciences 1127: 83–91.
- Krenzer KL, Dana MR et al. (December 2000). "Effect of androgen deficiency on the human meibomian gland and ocular surface". Journal of Clinical Endocrinolgy and Metabolism 85 (12): 4874–4882.
- Sullivan DA, Sullivan BD et al. (June 2002). "Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye". Annals of the New York Academy of Sciences 966: 211–222.
- Sullivan BD, Evans JE (December 2002). "Complete androgen insensitivity syndrome: effect on human meibomian gland secretions". Archives of Ophthalmology 120 (12): 1689–1699.
- Cermak JM, Krenzer KL et al. (August 2003). "Is complete androgen insensitivity syndrome associated with alterations in the meibomian gland and ocular surface?". Cornea 22 (6): 516–521.
- Oprea L, Tiberghien A et al. (October 2004). "Hormonal regulatory influence in tear film". Journal francais d'ophtalmologie 27 (8): 933–941.
- Hulshoff, Cohen-Kettenis et al. (July 2006). "Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure". European Journal of Endocrinology 155 (Suppl 1): 107–114. doi: . ISSN 0804-4643.
- MtF Hormone FAQ
- Tom Waddell Clinic Transgender Protocol - MTF and FTM clinical protocols aimed at providers
- Transsexual Road Map - Making informed decisions and setting realistic, achievable transition goals
- Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects - The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 8 3467-3473